MEDA: Astepro Patent Granted

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:

The United States Patent and Trademark Office (USPTO) today issued a patent related to Astepro (azelastine) nasal spray. This patent will be listed in the FDA’s Approved Drug Products List (the Orange Book). The Astepro patent is valid until 2028.

MORE ON THIS TOPIC